NANO MRNALtd Beheer

Beheer criteriumcontroles 1/4

De CEO NANO MRNALtd is Shiro Akinaga, benoemd in Dec2022, heeft een ambtstermijn van 1.92 jaar. bezit rechtstreeks 0.29% van de aandelen van het bedrijf, ter waarde ¥ 34.39M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 4.4 jaar.

Belangrijke informatie

Shiro Akinaga

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	1.9yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	4.4yrs

Recente managementupdates

Recent updates

Is NANO MRNALtd (TSE:4571) A Risky Investment?

Jul 18

CEO

Shiro Akinaga (68 yo)

1.9yrs

Tenure

Dr. Shiro Akinaga, Ph.D. serves as Director at NANO MRNA Co.,Ltd. (formerly known as NanoCarrier Co., Ltd.) since June 2020 and serves as its President and Chief Executive Officer since December 2022. Dr....

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Atsushi Matsumura	Executive Chairman of the Board	12.7yrs	geen gegevens	geen gegevens
Shiro Akinaga	President	1.9yrs	geen gegevens	0.29% ¥ 34.4m
Koji Fujimoto	CFO, MD of Corporate Division & Director	1.4yrs	geen gegevens	0.051% ¥ 6.0m

1.8yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 4571 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Atsushi Matsumura	Executive Chairman of the Board	12.7yrs	geen gegevens	geen gegevens
Shiro Akinaga	President	4.4yrs	geen gegevens	0.29% ¥ 34.4m
Koji Fujimoto	CFO, MD of Corporate Division & Director	4.4yrs	geen gegevens	0.051% ¥ 6.0m
Satoru Iino	Independent Director	12.7yrs	geen gegevens	geen gegevens
Teruo Okano	Independent External Director	28.4yrs	geen gegevens	0.46% ¥ 53.8m
Takashi Matsuo	Outside Audit & Supervisory Board Member	1.4yrs	geen gegevens	geen gegevens
Tetsuhito Matsuyama	Chairman of Standing Audit & Supervisory Board	1.4yrs	geen gegevens	0.19% ¥ 22.5m
Kazunori Kataoka	Independent Director	4.4yrs	geen gegevens	0.46% ¥ 53.8m
Yuki Hasegawa	Independent Director	3.4yrs	geen gegevens	geen gegevens
Seiichiro Wada	Outside Audit & Supervisory Board Member	1.4yrs	geen gegevens	geen gegevens

4.4yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4571 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

NANO MRNALtd Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

NANO MRNA Co.,Ltd., Annual General Meeting, Jun 27, 2024

NanoCarrier Co., Ltd., Annual General Meeting, Jun 29, 2023

NanoCarrier Co., Ltd., Annual General Meeting, Jun 27, 2022

Recent updates

NANO MRNA Co.,Ltd. to Report Q2, 2025 Results on Nov 14, 2024

First quarter 2025 earnings released: JP¥2.22 loss per share (vs JP¥2.73 loss in 1Q 2024)

New major risk - Share price stability

Is NANO MRNALtd (TSE:4571) A Risky Investment?

NANO MRNA Co.,Ltd. to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings released: JP¥11.10 loss per share (vs JP¥18.69 loss in FY 2023)

NANO MRNA Co.,Ltd., Annual General Meeting, Jun 27, 2024

New major risk - Share price stability

NANO MRNA Co.,Ltd. to Report Fiscal Year 2024 Results on May 14, 2024

NANO MRNA Co.,Ltd. to Report Q3, 2024 Results on Feb 14, 2024

NANO MRNA Co.,Ltd. to Report Q2, 2024 Results on Nov 10, 2023

New minor risk - Market cap size

NanoCarrier Co., Ltd. announced that it has received ¥13.6793 million in funding from Axcelead Inc., IPGaia, Inc.

NanoCarrier Co., Ltd. announced that it expects to receive ¥13.6793 million in funding from Axcelead Inc., IPGaia, Inc.

NanoCarrier Co., Ltd., Annual General Meeting, Jun 29, 2023

Third quarter 2023 earnings released: JP¥1.60 loss per share (vs JP¥6.24 loss in 3Q 2022)

NanoCarrier Co., Ltd. announced that it has received KRW 1.11096909 billion in funding from Whiz Partners Inc.

NanoCarrier Co., Ltd. to Report Q3, 2023 Results on Feb 14, 2023

Second quarter 2023 earnings released: JP¥7.99 loss per share (vs JP¥7.31 loss in 2Q 2022)

Second quarter 2023 earnings released: JP¥7.99 loss per share (vs JP¥7.31 loss in 2Q 2022)

NanoCarrier Co., Ltd. to Report Q2, 2023 Results on Nov 11, 2022

First quarter 2023 earnings released: JP¥4.67 loss per share (vs JP¥6.64 loss in 1Q 2022)

NanoCarrier Co., Ltd. to Report Q1, 2023 Results on Aug 10, 2022

Full year 2022 earnings released: JP¥26.89 loss per share (vs JP¥41.52 loss in FY 2021)

NanoCarrier Co., Ltd., Annual General Meeting, Jun 27, 2022

NanoCarrier Co., Ltd. to Report Fiscal Year 2022 Results on May 12, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: JP¥7.31 loss per share (vs JP¥27.69 loss in 2Q 2021)

First quarter 2022 earnings released: JP¥6.64 loss per share (vs JP¥3.30 loss in 1Q 2021)

NanoCarrier Co., Ltd. Commences in Domestic Patients Administration of VB-111, A Gene Therapy Product Global Phase III Trial in Platinum-Resistant Ovarian Cancer

Full year 2021 earnings released: JP¥41.52 loss per share (vs JP¥32.67 loss in FY 2020)

Third quarter 2021 earnings released: JP¥5.27 loss per share (vs JP¥3.65 loss in 3Q 2020)

New 90-day low: JP¥302

New 90-day low: JP¥334

Price target lowered to JP¥540

NanoCarrier Announces the Conclusion of NC-6004 Phase III Clinical Study for Pancreatic Cancer

Nanocarrier Co., Ltd. Starts Administering NC-6004 in the Phase IIb Clinical Study in Combination with Keytruda for Head and Neck Cancer

NanoCarrier Co., Ltd. to Report Q2, 2021 Results on Nov 12, 2020

NanoCarrier Co., Ltd. to Report Q1, 2021 Results on Aug 12, 2020

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd